Abstract

We previously demonstrated that blocking hepatocyte growth factor (HGF) receptor/c-Met signaling inhibited arthritis and articular bone destruction in mouse models of rheumatoid arthritis (RA). In the present study, we investigated the role of c-Met signaling in osteoblast differentiation using the C2C12 myoblast cell line derived from murine satellite cells and the MC3T3-E1 murine pre-osteoblast cell line. Osteoblast differentiation was induced by treatment with bone morphogenetic protein (BMP)-2 or osteoblast-inducer reagent in the presence or absence of either HGF antagonist (NK4) or c-Met inhibitor (SU11274). Osteoblast differentiation was confirmed by Runx2 expression, and alkaline phosphatase (ALP) and osteocalcin production by the cells. Production of ALP, osteocalcin and HGF was verified by enzyme-linked immunosorbent assay. Runx2 expression was confirmed by reverse transcription-PCR analysis. The phosphorylation status of ERK1/2, AKT, and Smads was determined by Western blot analysis. Both NK4 and SU11274 enhanced Runx2 expression, and ALP and osteocalcin production but suppressed HGF production in BMP-2-stimulated C2C12 cells. SU11274 also enhanced ALP and osteocalcin production in osteoblast-inducer reagent-stimulated MC3T3-E1 cells. SU11274 inhibited ERK1/2 and AKT phosphorylation in HGF-stimulated C2C12 cells. This result suggested that ERK and AKT were functional downstream of the c-Met signaling pathway. However, both mitogen-activated protein kinase/ERK kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) inhibitor suppressed osteocalcin and HGF production in BMP-2-stimulated C2C12 cells. Furthermore, SU11274, MEK, and PI3K inhibitor suppressed Smad phosphorylation in BMP-2-stimulated C2C12 cells. These results indicate that although the c-Met-MEK-ERK-Smad and c-Met-PI3K-AKT-Smad signaling pathways positively regulate osteoblast differentiation, c-Met signaling negatively regulates osteoblast differentiation, independent of the MEK-ERK-Smad and PI3K-AKT-Smad pathways. Therefore, blocking c-Met signaling might serve as a therapeutic strategy for the repair of destructed bone in patients with RA.

Highlights

  • Patients with rheumatoid arthritis (RA) often have severe systemic bone loss and increased risk of fracture due to increasedAbbreviations: ALP, alkaline phosphatase; bone morphogenetic proteins (BMPs), bone morphogenetic protein; ERK, extracellular signal-regulated kinase; HGF, hepatocyte growth factor; MAPK, mitogen-activated protein kinase; mitogen-activated protein kinase/ERK kinase (MEK), MAPK/ERK kinase; phosphatidylinositol 3-kinase (PI3K), phosphatidylinositol-3-kinase; RA, rheumatoid arthritis; RT-PCR, reverse transcription-polymerase chain reaction⇑ Corresponding author at: General Education Center, Hyogo University of HealthSciences, 1-3-6 Minatojima, Chuo-ku, Kobe, Hyogo 650-8530, Japan

  • Using C2C12 myoblasts, we examined the effect of NK4 on osteoblast differentiation

  • We previously reported that the HGF antagonist, NK4, inhibited arthritis and bone destruction by inhibiting angiogenesis and inflammatory cell infiltration in the synovium in SKG mice [15]

Read more

Summary

Introduction

Patients with rheumatoid arthritis (RA) often have severe systemic bone loss and increased risk of fracture due to increased⇑ Corresponding author at: General Education Center, Hyogo University of HealthSciences, 1-3-6 Minatojima, Chuo-ku, Kobe, Hyogo 650-8530, Japan. RANKL is expressed by T cells in the synovial tissues of RA patients [4]. Bone formation requires coordination between osteoblasts and osteoclasts. This coordination is mediated by multiple growth factors and cytokines [5]. The bone morphogenetic proteins (BMPs) are members of the transforming growth factor (TGF)-b superfamily, and they play a central role in bone formation [6]. BMPs are expressed preferentially in mesenchymal tissues prefiguring the future skeleton, developing bones, and differentiated chondrocytes and osteoblasts [7].

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.